Crossmark

C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells

Crossref DOI link: https://doi.org/10.1186/s12885-018-4387-5

Published Online: 2018-05-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Wei

Xu, Ling

Che, Xiaofang

Li, Haizhou

Zhang, Ye

Song, Na

Wen, Ti

Hou, Kezuo

Yang, Yi

Zhou, Lu

Xin, Xing

Xu, Lu

Zeng, Xue

Shi, Sha

Liu, Yunpeng

Qu, Xiujuan

Teng, Yuee http://orcid.org/0000-0002-9198-9795
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81172535, 81672605, 81673025, 31770963)

Natural Science Foundation of Liaoning Province (2015020458)

Department of Education of Liaoning Province (L2015588)

Jinzhou Science and Technology Project (17B1E37)
License Information

Text and Data Mining valid from 2018-05-02
More Information

Article History

Received: 8 June 2017

Accepted: 17 April 2018

First Online: 2 May 2018

Ethics approval and consent to participate

: We required ethics approval for the use of cell lines used in this study. Ethical approval was given by the Medical Science Research Ethics Committee of the First Affiliated Hospital of China Medical University (reference number 201121). The animal experiments were approved by the Animal Experimental Ethical Inspection Committee of Laboratory Animal Center, China Medical University (reference number 15018 M).

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.